Minneapolis (October 22, 2014) — Yukon Partners (“Yukon”), a provider of mezzanine capital for middle market private equity transactions, is pleased to announce its mezzanine capital and equity investment in AccuMED Innovative Technologies, Inc. (“AccuMED” or the “Company”), a manufacturer of textile-based medical products. The specific terms of the transaction were not disclosed.
MVC Private Equity Fund L.P. (“MVCPE”) sponsored the transaction whereby Yukon acquired a minority equity interest and MVCPE acquired a majority equity interest in AccuMED. Mezzanine capital was also provided by Yukon. BMO Harris Bank served as administrative agent on the senior credit facility with Fifth Third Bancorp also participating in the transaction and serving as the documentation agent. Management will own a meaningful interest in AccuMED and will continue to operate the business on a day-to-day basis.
AccuMED is a global, textile-based contract manufacturer focused on healthcare product companies and OEMs of medical devices and supplies, including respiratory disorder, vascular compression, and patient transfer products. The Company partners with global healthcare customers looking to rationalize specific manufacturing and capabilities to provide design, development and engineering, raw material sourcing, manufacturing and assembly, and inventory management.
The Company, which has nearly 1,000 employees, is headquartered in Buffalo, New York, with additional manufacturing operations in the Dominican Republic and Taiwan. The Company’s manufacturing capabilities include flame lamination, CNC die cutting, thermoforming, ultrasonic welding, programmable sewing, inspection, packaging, testing, warehousing and logistics.
MVCPE will complement the AccuMED management team’s vision with strategic guidance and financial expertise to accelerate growth while continuing to leverage the Company’s entrenched partnerships with its blue-chip customer base.
“Today’s announcement marks a milestone in our history,” said Mark Sater, CEO of AccuMED. “By working with two established financial firms, AccuMED has secured the capital and expertise necessary to execute our growth strategy. Yukon and MVCPE have a track record of successfully partnering with management teams to build value. We look forward to strengthening our relationship with both firms while working together to achieve our collective goals.”
“AccuMED holds a leading position in a niche industry with strong underlying fundamentals and opportunities for growth,” said Peter Seidenberg, Managing Director at MVCPE. “As healthcare costs continue to outpace inflation, the need for device manufacturers to deliver high quality, competitively-priced products has never been greater. We look forward to providing operational and strategic support to help AccuMED further cement its industry-leading position and take advantage of market opportunities.”
Bill Dietz, Managing Partner of Yukon added, “We are excited to partner with management and MVCPE to support the acquisition of AccuMED. The Company has established itself as a critical manufacturer of quality products for the healthcare industry. Yukon is fortunate to provide capital to AccuMED and to serve as a partner who values their strategic growth initiatives. We also look forward to benefiting from MVCPE’s investment stewardship.”
Based in Buffalo, NY, AccuMED is a world-class engineering services and contract manufacturing partner for major medical product companies with a specialty in textile-based class I/II medical products that touch the body. For more information on AccuMED, please visit www.accumedtech.com.
Yukon Partners is an independent and unaffiliated mezzanine firm primarily serving middle market private equity sponsored business transactions with a typical investment range of $10 to $40 million in the U.S. and Canada. The transactions in which Yukon invests include buyouts, growth and platform strategies, recapitalizations, mergers/acquisitions, and public-to-private buyouts. Yukon Partners is based in Minneapolis, Minnesota. For more information, please visit www.yukonpartners.com.
MVCPE seeks to build investor value by making control equity investments in lower middle-market companies across various industries. MVCPE targets companies at the lower end of the middle market, with annual revenue ranging from $10 million to $150 million and EBITDA of between $3 million and $25 million. Through its manager, The Tokarz Group Advisers, MVCPE is committed to delivering investor value by understanding the long-term business objectives of its portfolio companies and working with its management teams to achieve these goals. For more information, please visit www.mvccapital.com.
For more information, please contact: